ICOSL was found to be expressed by 7 of 12 glioma cell lines and neutralizing ICOSL antibodies reduced Th1 and Th2 cytokine levels in cocultures of PBMCs or T cell subsets with glioma cells [28]. This evidence concerns the gene ICOSLG and central nervous system cancer.